Analysts expect CytoDyn Inc. to report revenue of 0.00 for Q3 20, against a range of 0.00 to 0.00.
| Metric | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect CytoDyn Inc. to report earnings per share of -0.05 for Q3 20, against a range of -0.05 to -0.05.
| Metric | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | - | - | - | - | - | - | ||
| High Estimate | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.03 | ||
| Low Estimate | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.03 | ||
| Consensus Estimate | -0.05 | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.03 |